roteins of the STAT (signal transducer and activator of transcription) family are activated in response to cytokines and growth factors and promote proliferation, survival, and other biological processes (1-3). STATs are activated by phosphorylation of a critical tyrosine residue, which is mediated by growth factor receptor tyrosine kinases, Janus kinases, or the Src family kinases. Upon tyrosine phosphorylation, dimers of STATs formed between two phosphorylated monomers translocate to the nucleus, bind to specific DNA-response elements in the promoters of target genes, and induce gene expression. Aberrant activity of one of the family members, Stat3, contributes to carcinogenesis and tumor progression by up-regulating gene expression and promoting dysregulated growth, survival, and angiogenesis and modulating immune responses (2-9).
P
roteins of the STAT (signal transducer and activator of transcription) family are activated in response to cytokines and growth factors and promote proliferation, survival, and other biological processes (1) (2) (3) . STATs are activated by phosphorylation of a critical tyrosine residue, which is mediated by growth factor receptor tyrosine kinases, Janus kinases, or the Src family kinases. Upon tyrosine phosphorylation, dimers of STATs formed between two phosphorylated monomers translocate to the nucleus, bind to specific DNA-response elements in the promoters of target genes, and induce gene expression. Aberrant activity of one of the family members, Stat3, contributes to carcinogenesis and tumor progression by up-regulating gene expression and promoting dysregulated growth, survival, and angiogenesis and modulating immune responses (2-9).
As a critical step in STAT activation (10) , the dimerization between two STAT monomers presents an attractive target to abolish Stat3 DNA-binding and transcriptional activity and to inhibit Stat3 biological functions (11, 12) . Stat3 dimerization relies on the reciprocal binding of the SH2 domain of one monomer to the Pro-pTyr-Leu-Lys-Thr-Lys sequence of the other Stat3 monomer. To pursue the development of inhibitors of Stat3 signaling, key structural information gleaned from the x-ray crystal structure of the Stat3␤ homodimer (13) was used in the computational modeling and automated docking of small molecules into the SH2 domain of a Stat3 monomer, relative to the bound native pTyr peptide, to identify binders of the Stat3 SH2 domain, and potentially disruptors of Stat3⅐Stat3 dimers (14, 15) .
Structure-based high-throughput virtual screening of the National Cancer Institute (NCI) chemical libraries identified the high-scoring compound NSC 74859 (resynthesized as a pure sample and named S3I-201), which selectively inhibits Stat3 DNA-binding activity in vitro with an IC 50 value of 86 Ϯ 33 M. Furthermore, S3I-201 induces growth inhibition and apoptosis of malignant cells in part by constitutively inhibiting active Stat3 and induces human breast tumor regression in xenograft models.
Results
Computational Modeling and Virtual Screening. Our computational modeling and virtual screening study used the GLIDE (Grid-based Ligand Docking from Energetics) software (16, 17) (available from Schrödinger, Portland, OR) for the docking simulations and relied on the x-ray crystal structure of the Stat3␤ homodimer bound to DNA (13) determined at 2.25-Å resolution (1BG1 in the Protein Data Bank). For the virtual screening, DNA was removed and only one of the two monomers was used (see Fig. 1 ). To validate the docking approach, the native pTyr (pY) peptide, APpYLKT, was extracted from the crystal structure of one of the monomers and docked to the other monomer, whereby GLIDE produced a docking mode that closely resembled the x-ray crystal structure (data not shown). Three-dimensional structures of compounds from the NCI's chemical libraries were downloaded from the NCI Developmental Therapeutics Program web site (http://dtp.nci.nih. gov/docs/3ddatabase/Structuralinformation/structuraldata.html) and processed with LigPrep software (available from Schrödinger) to produce 2,392 3D structures for the Diversity Set and 150,829 3D structures for the Plated Set. Then GLIDE 2.7 SP (Standard Precision mode) docked each chemical structure (for small molecule) into the pTyr peptide-binding site within the SH2 domain of the monomer to obtain the best docking mode and docking score.
The best score observed from the docking studies was Ϫ11.7 kcal/mol, relative to the native phosphopeptide sequence APpYLK (scored as Ϫ11.9 kcal/mol). Typically, compounds receiving highly ⁄2 the potency (IC 50 value, 166 Ϯ 17 M). The appearance of different degrees of activity of S3I-201 at 300 M is due to the fact that different nuclear extract preparations were used, one from the v-Src-transformed mouse fibroblasts (NIH 3T3/v-Src) containing only activated Stat3 (Fig. 2 A Left) and the other from the EGFstimulated NIH 3T3/hEGFR that contains activated Stat1, Stat3, and Stat5 ( Fig. 2 A Right) . Supershift analysis with anti-Stat3 antibody shows protein⅐hSIE complex (Fig. 2 A Left, the last two lanes) contains Stat3, whereas use of anti-Stat1 antibody or antiStat5 antibody confirms that protein⅐MGFe complexes contain Stat1 or Stat5, respectively (Fig. 2 A Right, the last two lanes).
S3I-201 Disrupts Stat3⅐Stat3 Complex Formation in Vitro and in Intact
Cells. To provide experimental data in support of S3I-201's binding to Stat3, we asked whether unphosphorylated, inactive Stat3 monomer could interfere with the inhibitory effect of S3I-201 on active Stat3 DNA-binding (inactive Stat3 monomer will interfere with the inhibitory activity of S3I-201 if it interacts with the compound). To answer this question, cell lysates of unphosphorylated, inactive Stat3 monomer protein prepared from Sf-9 insect cells infected with only baculovirus containing Stat3, as previously described (11, 12, 18, 19) , and cell lysates of activated Stat3 dimer protein were mixed together; the mixture was preincubated with S3I-201 for 30 min before incubation with the radiolabeled hSIE probe and EMSA analysis carried out in the same manner as for Fig. 2 A. The unphosphorylated, inactive Stat3 monomer by itself had no significant effect on DNA-binding activity of activated Stat3 (Fig. 2B , compare lane 2 to lane 1), because inactive Stat3 monomer is incapable of binding DNA (19) . By contrast, the presence of inactive Stat3 monomer diminished the inhibitory effect of S3I-201 on the activated Stat3 in a dose-dependent manner, resulting in the recovery of the active Stat3 DNA-binding activity (Fig. 2B , lanes 5-7 versus lanes 3 and 4). The Stat3 DNA-binding activity that was otherwise inhibited (Fig. 2B, lanes 3 and 4) was partially or completely restored in the presence of 4 or 5 l of inactive Stat3 lysates, respectively (Fig. 2B, lanes 6 and 7) . These findings support the S3I-201-Stat3 interaction and suggest the interaction is independent of the activation status of Stat3. Similar studies were performed by using independently prepared cell lysates from Sf-9 insect cells infected with only the baculovirus containing Stat1, Stat5, or Src, as we have previously reported (11, 12, 18, 19) . In contrast to the effect observed with the inactive Stat3 monomer (Fig. 2B, lanes 5-7) , EMSA analysis showed that the presence of inactive Stat1, Stat5, or Src lysate induces no significant recovery of Stat3 DNA-binding activity (Fig. 2B , lanes 8-10, 11-13, and 14-16, respectively). In the case of the Stat1 monomer lysate, minimal recovery of Stat3 DNA-binding activity is observed (Fig. 2B , lane 10), which is evidence of a weak interaction of the Stat1 protein with S3I-201, as revealed in the initial evaluation ( Fig. 2 A Right) . The amounts of proteins for each of Stat1, Stat3, or Stat5 monomer or the Src lysate used in these studies was determined by SDS/PAGE and Western blot analysis to be similar (Fig. 2B , lanes [17] [18] [19] [20] .
To further confirm the interaction of S3I-201 with Stat3 and to demonstrate that it blocks Stat3⅐Stat3 dimerization in intact cells, Stat3 pull-down assays were performed. Viral Src transformed (NIH 3T3/v-Src) mouse fibroblasts stably expressing Stat3-YFP were transiently transfected with Flag-Stat3 (FLAG-ST3), treated either with 0.05% DMSO (control) or with S31-201 for 24 h, and then subjected to pull-down assay and SDS/PAGE. Western blot analysis for FLAG of whole-cell lysates shows equal expression of the FLAG-ST3 protein in the lysates in the transiently transfected cells in both the control and S3I-201-treated cells (Fig. 2Cii) . Western blot analysis probing with anti-FLAG antibody of the Stat3-YFP immunoprecipitates from control cells showed the presence of FLAG-ST3 protein ( Fig. 2Ci Upper Left, lane 1), suggesting Stat3-YFP and FLAG-ST3 proteins were pulled down together as a complex. By contrast, Western blot analysis probing with anti-FLAG antibody showed no detectable level of FLAG-ST3 protein in the Stat3-YFP immunoprecipitates from S3I-201-treated cells ( 
S3I-201 Does Not Interfere with Lck-SH2 Domain-Phosphotyrosine
Interaction. To further investigate the selectivity of S3I-201 and to rule out the possibility that it interacts with other SH2 domaincontaining proteins, we evaluated its effect on the binding between the unrelated Src family protein, Lck, and the cognate phosphopeptide, EPQpYEEIEL. We used the in vitro ELISA study involving the Lck-SH2-GST protein and the conjugate pTyr peptide, biotinyl--Ac-EPQpYEEIEL-OH (20), as described in Materials and Methods. Results from the ELISA show that the copresence of the Lck-SH2-GST protein and its cognate pTyr peptide results in signal induction (Fig. 2D, bar 4) , suggesting an interaction between the two (20) . The addition of 30 M and 100 M S3I-201 has no effect on the signal induction (Fig. 2D , compare bars 5 and 6 to bar 4), indicating that S3I-201 does not interfere with the binding of the Lck SH2 domain to its cognate pTyr peptide. (Fig. 2E, lanes 4-6) . By 24 h, constitutive Stat3 activation was significantly inhibited in all three cell lines (Fig. 2E , lanes 4-6 and 8, 10, and 12). Furthermore, SDS/PAGE and Western blot analysis of whole-cell lysates from NIH 3T3/v-Src fibroblasts show pTyr-705 Stat3 levels were significantly diminished after 24-h treatment with S3I-201 (Fig. 2F) , whereas the total Stat3 protein level remained unchanged. This inhibition of tyrosine phosphorylation may be explained by the fact that, by binding to the Stat3 SH2 domain, S3I-201 prevents Stat3 from binding to the pTyr motifs of the receptor tyrosine kinases and subsequently blocks de novo phosphorylation by tyrosine kinases. By contrast, SDS/PAGE and Western blot analysis performed on whole-cell lysates from mouse fibroblasts transformed by v-Src (NIH 3T3/v-Src) or overexpressing the human EGFR (NIH 3T3/ hEGFR) and stimulated by EGF revealed that treatment with S3I-201 for 24 h had no significant effect on the phosphorylation of Shc (pShc), Erk1/2 (pErk1/2), or Src (pSrc) in cells (SI Fig. 7 ). Total Erk1/2 protein levels were unchanged. Moreover, SDS/PAGE and Western blot analysis with the anti-pTyr antibody 4G10 showed no significant changes in the pTyr profile of NIH 3T3/v-Src fibroblasts after 24-h treatment with S3I-201 (SI Fig. 7 ).
Selective Inhibition of Stat3 Transcriptional Activity by S3I-201. We investigated S3I-201's effect on Stat3-dependent transcriptional activity. Normal mouse fibroblasts (NIH 3T3) were transiently cotransfected with the Stat3-dependent luciferase reporter pLucTKS3 and a plasmid encoding the v-Src oncoprotein that activates Stat3, and cells were untreated (0.05% DMSO, control) or treated with S3I-201. As previously reported (23), v-Src protein mediated induction of the Stat3-dependent luciferase reporter pLucTKS3 activity by Ϸ7-fold (Fig. 3 Left) . This Stat3-dependent pLucTKS3 induction was significantly inhibited by the treatment of cells with S3I-201 in a dose-dependent manner (Fig. 3 Left) . To examine specificity of effects, normal mouse fibroblasts were cotransfected with the Stat3-independent luciferase reporters pLuc-SRE (23) or ␤-casein promoter-driven Luc (24) together with v-Src plasmid and treated with S3I-201 or without (0.05% DMSO). In contrast to the effect on the induction of pLucTKS3 luciferase reporter, v-Src-mediated induction of Stat3-independent pLucSRE (23) or the ␤-casein promoter-driven Luc (24) was not affected by treatment with S3I-201 ( Fig. 3 Center and Right).
S3I-201 Blocks Anchorage-Dependent and Independent Growth only in
Cells Where Stat3 is Persistently Activated. We next determined whether this Stat3 activity inhibitor is able to inhibit the anchoragedependent and -independent (transformation) growth of human and mouse cancer cell lines. The human breast carcinoma (MDA-MB-231, MDA-MB-435, and MDA-MB-468) cell lines and the v-Src-transformed mouse fibroblasts (NIH 3T3/v-Src), which har- bor constitutively active Stat3 and the human breast carcinoma MDA-MB-453 cell line and normal mouse fibroblasts (NIH 3T3), which do not harbor aberrant Stat3 activity, were treated with S3I-201 and analyzed for viable cell number by trypan blue exclusion and microscopy (Fig. 4A) . S3I-201 significantly reduced viable cell numbers and inhibited growth of transformed mouse fibroblasts NIH 3T3/v-Src and breast carcinoma cell lines (MDA-MB-231, MDA-MB-435, and MDA-MB-468) (Fig. 4A) . By contrast, growth and viability of normal mouse fibroblasts (NIH 3T3) and the breast carcinoma cell line (MDA-MB-453) without aberrant Stat3 activity were not significantly altered (Fig. 4A) . Furthermore, growth of v-Src-transformed mouse fibroblasts in soft-agar suspension is significantly inhibited by S3I-201 (Fig. 4B) . By contrast, soft-agar growth of the v-Ras-transformed counterpart (NIH 3T3/ v-Ras), which is independent of constitutively active Stat3, is unaffected by treatment with S3I-201 (Fig. 4B ).
S3I-201 Preferentially Induces Apoptosis of Malignant Cells Harboring
Constitutively Active Stat3. To determine whether the S3I-201 induced loss of tumor cell viability was due to apoptosis, the human breast carcinoma cell lines MDA-MB-453 and MDA-MB-435 and the normal mouse fibroblasts (NIH 3T3) and their v-Srctransformed counterpart (NIH 3T3/v-Src) were untreated (0.05% DMSO, control) or treated with S3I-201 for 48 h and analyzed by annexin V binding and flow cytometry. At 30-100 M, S3I-201-induced significant apoptosis in the representative human breast carcinoma cell line MDA-MB-435 and NIH 3T3/v-Src, both of which harbor constitutively active Stat3 (Fig. 5A) . The breast carcinoma MDA-MB-435 cell line is more sensitive to 30 M S3I-201 (Fig. 5A) . By contrast, the human breast cancer MDA-MB-453 cells and the normal mouse fibroblasts (NIH 3T3), which do not contain abnormal Stat3 activity, are less sensitive to S3I-201 at 100 M or less (Fig. 5A ). At 300 M or higher, S3I-201 induced general, nonspecific cytotoxicity independent of Stat3 activation status.
We reasoned that if the ability of S3I-201 to induce tumor cell apoptosis is due to its ability to inhibit Stat3 activation, then the constitutively dimerized and persistently activated Stat3C (25) should rescue cells from S3I-201-induced apoptosis. To this end, the breast carcinoma MDA-MB-231 cells, which harbor activated Stat3, were transiently transfected with Stat3C and evaluated for apoptosis. Consistent with results in Fig. 5A , S3I-201 induced 50-80% apoptosis in untransfected or mock-transfected human breast carcinoma MDA-MB-231 cells (Fig. 5B Left) . By contrast, cells transfected with Stat3C and treated with S3I-201 showed greatly diminished apoptosis (Fig. 5B Left) , Ͻ2-fold compared with 9-or 5-fold apoptosis in nontransfected or mock-transfected cells, respectively. There is an increase in the background level of cell death, which could be due to the effects of transfection.
To establish that the effect of S3I-201 is due to its interaction with the Stat3 SH2 domain, similar studies were performed in cells that were transiently transfected with an expression vector for either the N-terminal region of Stat3 (ST3-NT) or the Stat3 SH2 domain (ST3-SH2) and treated with or without S3I-201. Annexin V binding and flow cytometry showed that although mock-transfected cells were strongly induced by S3I-201 to undergo apoptosis (Fig. 5B  Right) , similar to the Stat3C-transfected cells, the overexpression of the Stat3-SH2 domain diminished the apoptotic effects of S3I-201 (Fig. 5B Right) . In contrast, ST3-NT has no effect on the ability of S3I-201 to induce apoptosis of malignant cells (Fig. 5B Right) .
S3I-201 Represses the Expression of the Stat3-Regulated Genes En-
coding Cyclin D1, Bcl-xL, and Survivin. To investigate the molecular mechanisms for the cell growth inhibition and apoptosis by S3I-201, we examined the expression of the known Stat3 target genes in the v-Src-transformed mouse fibroblasts (NIH 3T3/v-Src) and the human breast carcinoma MDA-MB-231 cell line, which harbor constitutively active Stat3. Immunoblot analysis of whole-cell lysates showed significant reduction in expression of the cyclin D1, Bcl-xL, and survivin proteins in response to S3I-201 treatment (Fig.  5C ), indicating that S3I-201 represses induction of the cell cycle and anti-apoptotic regulatory genes in malignant cells.
S3I-201 Induces Regression of Human Breast Tumor Xenografts.
We extended these studies to evaluate the antitumor efficacy of S3I-201 in mouse models with human breast tumor xenografts that harbor constitutively active Stat3. Human breast (MDA-MB-231) tumorbearing mice were given an i.v. injection of S3I-201 or vehicle every 2 or every 3 days for 2 weeks, and tumor measurements were taken every 2-3 days. Compared with control (vehicle-treated) tumors, which continued to grow, human breast tumors in mice that received S3I-201 displayed strong growth inhibition (Fig. 6A) . Continued evaluation of treated mice on termination of treatment showed no resumption of tumor growth (data not shown), suggesting potentially a long-lasting effect of S3I-201 on tumor growth. To determine that target was inhibited by S3I-201, lysates were prepared from tumor tissue from one control animal and from the residual tumor tissue in two treated-mice for Stat3 DNA-binding activity in vitro, as we have previously done (18) . EMSA analysis showed strong inhibition of Stat3 DNA-binding activity in residual tumor tissue from mice treated with S3I-201 (T1 and T2) compared with control tumor (Fig. 6B, lanes 1-3) . See SI Results for SDS/ PAGE and Western blot analysis of lysates. Moreover, EMSA analysis of in vitro Stat3 DNA-binding activity also showed that preincubation of lysates of equal total protein from control tumor tissue with 10, 30, and 100 M S3I-201 before incubation with radiolabeled hSIE probe resulted in a dose-dependent abrogation of Stat3 activity (Fig. 6B, lanes 4-6) , as observed originally in Fig.  2 A Left. Together these studies establish the proof-of-concept for the antitumor effect of S3I-201 in tumors that harbor constitutively active Stat3.
Discussion
The present study demonstrates the feasibility of using x-ray crystallographic data and computational modeling as a basis for a structure-based virtual screening to identify chemical probes and small-molecule binders of the Stat3 SH2 domain. Similar computational analysis has been applied in the development of inhibitors of Stat3 and other proteins (14, 15) . The docking pose of S3I-201 suggests that its aminosalicylic moiety mimics the phenylphosphate group of the PpYLKT motif. Furthermore, its carboxyl group is hydrogen bonded to Arg-609, Ser-611, and Ser-613 of Stat3, while the phenolic hydroxyl group is hydrogen-bonded to Lys-591. Moreover, the proximity of the Lys-591 to the benzene ring with the phenolic hydroxyl group suggests the possibility of a stabilizing -electron-cation interaction. Also, the tolyl group is buried within a partially hydrophobic pocket, which contains the tetramethylene portion of the side chain of Lys-592 and the trimethylene portion of the side chain of Arg-595, along with residues Ile-597 and Ile-634. We believe that these features (the phosphate mimic and hydrophobic side chain) combine and explain how S3I-201 binds to the SH2 domain of Stat3.
The native pTyr peptide inhibitor of Stat3, PpYLKTK, was previously shown to disrupt Stat3⅐Stat3 dimerization, thereby inducing antitumor cell effects (12) . In pull-down assays, we demonstrated that S3I-201 disrupts the complex formation between two Stat3 monomers. S3I-201 preferentially interacts with Stat3 monomer protein over Stat1 or the Src family protein and has 1 ⁄2 the affinity for Stat5. In cells, the interactions with Stat3 will prevent de novo phosphorylation and activation of Stat3 monomer. Thus, S3I-201 mediates selective inhibition of Stat3 transcriptional activity and induces cell growth inhibition, loss of viability, and apoptosis of malignant cells that harbor constitutively active Stat3, as well as blocks v-Src transformation, events that are all consistent with the abrogation of Stat3 activation (11, 12, 22, 26, 27) . The observation that overexpressed exogenous Stat3 SH2 domain, but not Stat3 N terminus in malignant cells, protects against S3I-201-induced apoptosis strongly supports the Stat3 SH2 domain as the target of S3I-201. Our findings further suggest the antitumor cell effects of S3I-201 are mediated by suppressing aberrant Stat3-induced dysregulation of the cell-cycle control and the anti-apoptotic genes. Furthermore, in vivo antitumor effects of S3I-201 in human breast tumor xenografts establish the proof-of-concept for the therapeutic potential of S3I-201 as a Stat3 inhibitor in human tumors that harbor constitutively active Stat3.
Here, we report a Stat3 SH2 domain binder and an inhibitor of Stat3 signaling, which is structurally different from previously identified dimerization disrupters, peptides and peptidomimetics (11, 12) , or other Stat3 inhibitors, such as the G-quartet oligonucleotides (28), peptide aptamers (29) , platinum (IV) complexes (18, Three days after the last S3I-201 injection, animals were killed, tumors from one control animal (DMSO-treated) or residual tumor tissue from two S3I-201-treated (T1 and T2) mice were extracted, and lysate preparations with equal total proteins were analyzed for Stat3 activation by incubating with radiolabeled hSIE probe and subjecting the products to EMSA analysis (lanes 1-3) , or lysates from control tumor tissue of equal total proteins were preincubated with or without increasing concentrations of S3I-201 before incubation with radiolabeled hSIE probe and subjecting the products to EMSA analysis (lanes 1, 4, 5, and 6) . Positions of Stat3⅐DNA complexes are shown.
19), cucurbitacin (30) , and STA-21 (NSC 628869) (15) . Although SH2 domains have been noted to have a high sequence similarity in their 100 amino acids (31, 32) , S3I-201 has preference for Stat3 in that at concentrations that inhibit Stat3, S3I-201 has a low effect on Stat1 and Stat5, no interaction with the Src family proteins, weak inhibition of Erk1/2 and Shc activation, and low toxicity to cells with no aberrant Stat3. Our study supports computational modeling application in structure-based virtual screening for identifying Stat3 inhibitors from chemical libraries, and together with another report (15) is among the first to identify Stat3 inhibitors by this approach. Twelve to 24 h after seeding, cells were transfected with the appropriate plasmids. For detailed procedure information, see SI Materials and Methods. Twenty-four hours after transfection, cells were untreated (0.05% DMSO) or treated with S3I-201 (100 M) for an additional 24 h and harvested, and cytosolic extracts were prepared for luciferase assay, as described (11, 23) , or cells were analyzed by annexin V binding and flow cytometry.
Materials and Methods
Cytosolic Extracts and Cell Lysate Preparation, Luciferase and ␤-Galactosidase Assay. Cytosolic extract preparation from mammalian cells for luciferase (Promega, Madison, WI) and ␤-galactosidase assays, and from recombinant baculovirus-infected Sf-9 cells to obtain Stat1, Stat3, and Stat5 monomers, and Src proteins are as described previously (11, 23, 34) .
Nuclear Extract Preparation, EMSAs, and Densitometric Analysis.
Nuclear extract preparations and EMSAs were carried out as previously described (21) (22) (23) . The 32 P-labeled oligonucleotide probes used were hSIE that binds Stat1 and Stat3 (22, 35) and MGFe for Stat1 and Stat5 binding (36, 37) . Except where indicated, nuclear extracts were preincubated with compound for 30 min at room temperature before incubation with the radiolabeled probe. Bands corresponding to DNA-binding activities were scanned and quantified for each concentration of compound and plotted as a percentage of control (vehicle) against concentration of compound; the IC 50 values were derived from these plots, as previously reported (11, 19) .
Immunoprecipitation (IP) and Western Blotting. Whole-cell lysates and tumor tissue lysates from pulverized tumor tissue were prepared in boiling SDS sample loading buffer to extract total proteins, as previously described (12, 18, 19, 22) . For detailed procedure information and IP, see SI Materials and Methods.
Lck-SH2 Domain-Phosphopeptide-Binding Assay. In vitro ELISA study involving the Lck-SH2-GST protein and the conjugate pTyr peptide, biotinyl--Ac-EPQpYEEIEL-OH (Bachem Biosciences, King of Prussia, PA) was performed as previously described (20) . For detailed procedure information, see SI Materials and Methods.
Soft-Agar Colony-Formation Assay. Colony formation assays were carried out in six-well dishes, as described previously (11) . Treatment with S3I-201 was initiated 1 day after seeding cells by adding 100 l of medium with or without S3I-201 and repeating every 3 days, until large colonies were evident.
Measurement of Apoptosis by Flow Cytometry. Proliferating cells were treated with or without S3I-201 for up to 48 h. In some cases, cells were first transfected with Stat3C, ST3-NT, or ST3-SH2 domain or mock-transfected for 24 h before treatment with compound for an additional 24-48 h. Cells were then detached and analyzed by annexin V binding (BD Biosciences, San Diego, CA) according to the manufacturer's protocol and flow cytometry to quantify the percent apoptosis.
Mice and in Vivo Tumor Studies. Six-week-old female athymic nude mice were purchased from Harlan (Indianapolis, IN) and maintained in the institutional animal facilities approved by the American Association for Accreditation of Laboratory Animal Care. Athymic nude mice were injected in the left flank area s.c. with 5 ϫ 10 6 human breast cancer MDA-MB-231 cells in 100 l of PBS. After 5-10 days, tumors with a diameter of 3 mm were established. Animals were given S3I-201 i.v. at 5 mg/kg every 2 or 3 days for 2 weeks and monitored every 2 or 3 days. Animals were stratified so that the mean tumor sizes in all treatment were nearly identical. Tumor volume was calculated according to the formula V ϭ 0.52 ϫ a 2 ϫ b, where a is the smallest superficial diameter and b is the largest superficial diameter.
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